NUVB | Nuvation Bio Inc. | [NYSE]
Index- P/E- EPS (ttm)-0.48 Insider Own27.02% Shs Outstand218.74M Perf Week-7.65%
Market Cap351.54M Forward P/E- EPS next Y-0.55 Insider Trans0.41% Shs Float159.95M Perf Month-2.48%
Income-104.60M PEG- EPS next Q-0.11 Inst Own65.40% Short Float / Ratio1.30% / 3.87 Perf Quarter-19.07%
Sales- P/S- EPS this Y-9.60% Inst Trans-8.38% Short Interest2.07M Perf Half Y-14.21%
Book/sh2.93 P/B0.54 EPS next Y-19.60% ROA-15.30% Target Price4.08 Perf Year-54.76%
Cash/sh2.89 P/C0.54 EPS next 5Y- ROE-15.80% 52W Range1.52 - 4.31 Perf YTD-18.23%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-63.57% Beta-
Dividend %- Quick Ratio52.00 Sales past 5Y- Gross Margin- 52W Low3.29% ATR0.07
Employees53 Current Ratio52.00 Sales Q/Q- Oper. Margin- RSI (14)41.28 Volatility4.00% 4.47%
OptionableYes Debt/Eq0.00 EPS Q/Q0.50% Profit Margin- Rel Volume1.15 Prev Close1.61
ShortableYes LT Debt/Eq0.00 EarningsMay 04 AMC Payout- Avg Volume536.16K Price1.57
Recom2.20 SMA20-3.59% SMA50-6.24% SMA200-23.89% Volume618,469 Change-2.48%
Date Action Analyst Rating Change Price Target Change
Jan-06-23Downgrade Jefferies Buy → Hold $5 → $2
Aug-02-22Downgrade BTIG Research Buy → Neutral
Aug-02-22Downgrade BMO Capital Markets Outperform → Market Perform $8 → $2.50
May-04-22Initiated H.C. Wainwright Buy $14
Oct-15-21Resumed BTIG Research Buy $16
Apr-06-21Initiated RBC Capital Mkts Outperform $15
Mar-08-21Initiated Wedbush Outperform $20
Mar-08-21Initiated Jefferies Buy $20
Mar-08-21Initiated Cowen Outperform
Mar-08-21Initiated BTIG Research Buy $16
Mar-08-21Initiated BMO Capital Markets Outperform $16
May-16-23 06:23AM
May-04-23 04:05PM
Mar-21-23 05:10PM
Mar-18-23 06:48PM
Mar-15-23 04:05PM
05:05AM Loading…
Feb-17-23 05:05AM
Jan-17-23 08:19AM
Dec-19-22 04:05PM
Dec-07-22 05:03AM
Nov-03-22 04:05PM
Aug-11-22 10:01AM
Aug-10-22 08:45AM
Aug-04-22 04:05PM
Aug-01-22 04:00PM
08:00AM Loading…
Jul-27-22 12:00PM
Jul-18-22 07:00AM
Jun-27-22 08:52AM
May-23-22 11:36AM
May-09-22 04:05PM
Feb-28-22 04:05PM
Jan-21-22 10:21AM
Jan-20-22 08:43AM
Jan-14-22 12:31PM
Jan-10-22 07:00AM
Dec-17-21 08:00AM
Dec-15-21 07:00AM
10:33AM Loading…
Dec-13-21 10:33AM
Dec-08-21 07:00AM
Nov-19-21 08:24AM
Nov-10-21 04:05PM
Oct-25-21 09:12AM
Sep-20-21 04:14PM
Aug-12-21 04:05PM
Jul-06-21 10:20AM
Jun-01-21 07:00AM
May-26-21 07:00AM
May-21-21 04:34PM
May-17-21 05:00PM
May-11-21 05:51AM
Apr-17-21 09:36PM
Mar-11-21 05:15PM
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform that focuses on targeting an inhibitor of poly ADP ribose polymerase (PARP) to anti-cancer warheads of existing drugs, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer. Nuvation Bio Inc. was founded in 2018 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
FALBERG KATHRYN EDirectorDec 05Buy1.9543,00083,962250,000Dec 05 05:10 PM
FALBERG KATHRYN EDirectorDec 02Buy1.9847,00093,187207,000Dec 05 05:10 PM
FALBERG KATHRYN EDirectorDec 01Buy1.9784,959167,599160,000Dec 05 05:10 PM
FALBERG KATHRYN EDirectorNov 30Buy1.8575,041139,08875,041Dec 05 05:10 PM